All In Biotech

Drug Trial Radar · NCT02494895

Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)

Last checked: Nov 19, 2026Latest source record: Jun 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 3,056 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,056

Planned (sponsor's estimate)

Start

Aug 1, 2015

Primary completion

May 2023

Study completion May 2023

Sponsor

Lead sponsor
Yonsei UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 19 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the clinical outcomes of dual antiplatelet therapy with aspirin and ticagrelor vs. ticagrelor monotherapy at 3 months after PCI in patients with acute coronary syndrome.

Conditions

  • Acute Coronary Syndrome

Interventions

  • Ticagrelor monotherapyDrug

    Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.

  • Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)Drug

    Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major adverse cardiovascular clinical events (MACCE)Time frame: 1 year after the procedure
  2. major bleedingTime frame: 1 year after the procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.